Eloralintide vs Larazotide Acetate
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
EloralintideRecovery & Repair
Larazotide Acetate- Summary
- Eloralintide is a long-acting amylin analog under development by OPKO Health. Amylin is co-secreted with insulin and regulates post-meal glucose by slowing gastric emptying, suppressing glucagon, and promoting satiety. Eloralintide is designed for once-weekly dosing, differentiating it from the short-acting pramlintide (Symlin). It is being studied for obesity and type 2 diabetes as a complement to GLP-1 based therapies.
- Larazotide acetate is an 8-amino acid peptide (Gly-Gly-Val-Leu-Val-Gln-Pro-Gly) derived from Zonula Occludens Toxin (ZOT) of Vibrio cholerae. It paradoxically acts as a ZOT antagonist to close tight junctions and reduce intestinal permeability ('leaky gut'). It is the most advanced clinical compound targeting gut permeability directly.
- Half-Life
- ~7 days (estimated, long-acting design)
- Local gut action; minimal systemic exposure
- Admin Route
- SubQ
- Oral
- Research
- —
- —
- Typical Dose
- Under investigation in Phase 1/2 trials
- 0.5-2 mg
- Frequency
- Once weekly
- 3x daily
- Key Benefits
- Once-weekly dosing (vs multiple daily injections for pramlintide)
- Appetite suppression via central amylin receptor activation
- Reduction in post-meal glucagon secretion
- Complementary mechanism to GLP-1 agonists for combination therapy
- Slows gastric emptying for prolonged satiety
- Potential additive weight loss when combined with GLP-1 agents
- Directly reduces intestinal tight junction permeability
- Clinical efficacy in celiac disease (Phase 3 trials)
- Reduces systemic inflammation from gut permeability
- Targets root cause of leaky gut (Zonulin pathway)
- Local gut action without systemic absorption
- Potential application in IBS, IBD, autoimmune conditions
- Side Effects
- Nausea
- Vomiting
- Decreased appetite
- Injection site reactions
- +1 more
- Headache (mild, dose-dependent)
- Nausea (rare)
- Well-tolerated overall in clinical trials
- Stacks With
- —
- —